VEGFA and pheochromocytoma-paraganglioma: The academic First International Randomized phase II Study in Malignant Progressive Pheochromocytoma and Paragangliomas (FIRSTMAPP) study25 randomized 78 patients with these very rare tumours with strong expression of vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF) and VEGF receptor (VEGFR)-1,2 and PDGF receptor (PDGFR), to sunitinib [37.5 mg once daily shown to be effective in pancreatic neuroendocrine tumours (NETs26)] or placebo.